Cytomegalovirus viremia appeared in 59% of adults with advanced HIV disease in a Johannesburg cohort, according to findings published on September 30, 2026, in Open Forum Infectious Diseases, Medscape reported. The detection of the virus carried a stark prognostic weight, driving up 6-month mortality rates significantly compared with patients who tested negative for the infection.
Johannesburg Hospital Study Tracks Advanced HIV Outcomes
Researchers from the London School of Hygiene & Tropical Medicine led the post hoc analysis of a prospective cohort study at two hospitals in Johannesburg. The investigation enrolled 146 adult outpatients between June 2015 and October 2017. Participants had advanced HIV disease and CD4 counts below 200 cells/uL. The median age of the cohort was 39 years, and half the participants were men. Investigators screened all candidates for the cryptococcal antigen before enrollment, excluding individuals with symptomatic cryptococcal meningitis or those already receiving treatment for it.
Baseline plasma samples revealed that 86 participants, or 59%, had detectable CMV DNA. Among those testing positive, the median viral load reached 366 IU/mL. Researchers conducted telephone follow-ups with participants for 6 months. This tracking gathered data on hospitalization events, causes of death, and incident opportunistic infections, including tuberculosis and cryptococcal disease.
Mortality Rates Climb Sharply Among CMV-Positive Outpatients
The 6-month mortality rate reached 26% among participants who had baseline CMV viremia, compared with just 7% in those without the virus, establishing a statistically significant difference with a $P$ value of .003. Logistic regression models adjusted for baseline CD4 count, antiretroviral therapy status, age, and sex. Even after these adjustments, CMV viremia remained independently associated with increased odds of 6-month mortality, yielding an adjusted odds ratio of 4.02 with a $P$ value of .02.
Despite the sharp rise in mortality, CMV viremia showed no significant statistical association with a diagnosis of incident cryptococcal disease or tuberculosis at any point during the follow-up window. The authors reported no conflicts of interest.
Observational Limits and Outpatient Prognosis
Study authors noted that the prognostic significance of CMV viremia may prove more pronounced in outpatients with advanced HIV disease than among seriously unwell hospitalized patients. Because the investigation relied on an observational design, it could not establish a direct cause-and-effect relationship, leaving open the possibility of unmeasured confounders. Furthermore, the cohort featured a deliberate overrepresentation of participants with cryptococcal antigenemia, a factor that may have inflated absolute mortality estimates relative to an unselected population with advanced disease. Telephone-based tracking without systematic testing likely missed some tuberculosis cases.
Frequently Asked Questions
Why were patients with symptomatic cryptococcal meningitis excluded from the study?
Researchers excluded individuals with symptomatic cryptococcal meningitis or those actively receiving treatment for it to isolate the specific mortality risks and clinical outcomes associated with baseline cytomegalovirus viremia in outpatients with advanced HIV disease.
How was participant follow-up conducted over the 6-month period?
Investigators conducted follow-ups via telephone for 6 months to collect records on hospitalization events, specific causes of death, and incident opportunistic infections like tuberculosis and cryptococcal disease.
Related reading